Five things for pharma marketers to know: Friday, September 15, 2017

Share this content:


1. The FDA approved Allergan and Amgen's Mvasi, a biosimilar version of Roche's Avastin. Mvasi becomes the first biosimilar cancer treatment to receive FDA approval. (Reuters)

2. The regulator also approved Bayer's Aliqopa as a treatment for relapsed follicular lymphoma. The drug is expected to have peak sales of $600 million a year. (Endpoints News)

3. Enrollment in late-stage clinical trials for gynecological cancer has plummeted, falling 90% from 2011 to 2016. (NYT)

4. A new law in Maryland, set to go into effect October 1, will track and require state investigations into “unconscionable increases” in what are considered essential generic drugs. Drugmakers have sought a court injunction against the law. (Reuters)

5. Dr. Vinay Prasad, a physician in Portland, Ore., has become a prominent critic of drug costs, conflicts of interest in medicine, and bad clinical-trial design. (Stat)

Share this content:
Scroll down to see the next article